Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Pramand LLC has 3 pending office actions in the Biotechnology & Pharmaceuticals technology area. These actions are assigned to 3 distinct examiners across 3 distinct art units. JAGADISHWAR RAO SAMALA is the busiest examiner for the company with 1 pending office action. Each of the 3 pending office actions is being handled by a different examiner in a separate art unit.
The distribution of 3 pending office actions across 3 distinct examiners suggests a variety of individual examination styles for the company to manage. Because the 3 pending office actions are spread across 3 distinct art units, the company must address different examination practices within the Biotechnology & Pharmaceuticals field. JAGADISHWAR RAO SAMALA, as the busiest examiner with 1 pending office action, manages one-third of the current active workload. This 3 distinct examiners and 3 distinct art units structure requires the company to manage 3 separate sets of deadlines and examiner expectations.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| SAMALA, JAGADISHWAR RAO | 1 | 67.9% | +55.7% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18226169 | CHEMICAL TISSUE ABLATION WITH HYDROGEL MATRIX AND CORRESPONDING MEDICAL APPLICATIONS | SAMALA, JAGADISHWAR RAO | 62d |
| Art Unit | Apps |
|---|---|
| 1618 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18226169 | CHEMICAL TISSUE ABLATION WITH HYDROGEL MATRIX AND CORRESPONDING MEDICAL APPLICATIONS | SAMALA, JAGADISHWAR RAO | 1618 | §103 | Final Rejection | 62d | Pending | Jul 25, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialPramand LLC has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Jagadishwar Rao Samala has the most, with 1 of Pramand LLC's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
